How Did Fisher & Paykel Healthcare (ASX:FPH), Ansell (ASX:ANN), and Clinuvel Pharmaceuticals (ASX:CUV) Perform on 5 November 2026?

• Ansell (ASX:ANN) closed at A$45.52, gaining 4.40%, following FY26 full-year results that showedEarningsgrowth in dynamic market conditions.

Sonal Goyal | 05 November 2026

Can Nanosonics (ASX:NAN) Accelerate Growth With Its CORIS System Launch in FY27?

• The CORIS System is planned for commercial launch across the UK, Ireland and Australia in H1 FY27, with a US launch to follow.

Sonal Goyal | 05 November 2026

• Neuren upgraded its 2026 total income guidance from trofinetide to US$91-93 million, including a US$35 million milestone from DAYBU's German launch

Sonal Goyal | 05 November 2026

• NetDebtwas reduced by NZ$121.4 million to NZ$506.7 million, bringing gearing to 30.1% at the lower end of the target range

Sonal Goyal | 05 November 2026

• The deal includes the full stack — Visage 7 Viewer, Workflow, and Open Archive — plus legacy PACS migration

Sonal Goyal | 05 November 2026

• The contract includes Visage 7 Viewer, Workflow, Open Archive, and notably Visage 7 Cardiology Imaging

Sonal Goyal | 05 November 2026

• The company's newManufacturingFacilityconstruction was completed, with validation activities progressing ahead of FY27 transition.

Sonal Goyal | 05 November 2026

• PYC-003 progressed to dosing at 2.4 mg/kg in the Phase 1b Multiple Ascending Dose study for polycystic kidney disease

Sonal Goyal | 05 November 2026

• The first patient was safely treated with RC220 and osimertinib in the HARNESS-1 trial for EGFR-mutated non-small cell lung cancer

Sonal Goyal | 05 November 2026

• The company declared total FY26 dividends of 18.40 cents per share, up 13% on the prior comparable period.

Sonal Goyal | 05 November 2026